Real-world effectiveness and tolerability of highly purified cannabidiol in patients with monogenic developmental and epileptic encephalopathies with highly active epilepsy.
Cerulli Irelli E, Mazzeo A, Caraballo RH, Perulli M, Moloney PB, Peña-Ceballos J, Simeone N, Mieszczanek TS, Marini L, Licchetta L, De Giorgis V, Reyes Valenzuela G, Casellato S, Cesaroni E, Operto FF, Domínguez-Carral J, Ramírez-Camacho A, Ferretti A, Santangelo G, Aledo-Serrano A, Rüegger A, Mancardi MM, Prato G, Riva A, Bergonzini L, Cordelli DM, Bonanni P, Bisulli F, Di Gennaro G, Matricardi S, Striano P, Delanty N, Marini C, Battaglia DI, Di Bonaventura C, Ramantani G, Gardella E; GENE-CBD study group.
Cerulli Irelli E, et al. Among authors: ramantani g.
Epilepsy Behav. 2026 Apr 14;180:111036. doi: 10.1016/j.yebeh.2026.111036. Online ahead of print.
Epilepsy Behav. 2026.
PMID: 41985207
No abstract available.